All In Biotech

Drug Trial Radar · NCT05650229

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 13, 2022

Primary completion

Oct 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

Conditions

  • Primary Mitochondrial Disease

Interventions

  • KL1333Drug

    Twice daily

  • PlaceboDrug

    Twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in-patient-reported fatigue symptoms and impacts on daily living measured by Patient-Reported Outcomes Measurement Information System (PROMIS®) Fatigue PMD Short FormTime frame: Baseline and 48 Weeks
  2. Change in 30 Second Site-to-Stand Test.Time frame: Baseline and 48 Weeks

Locations

55 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California, Irvine - ALS & Neuromuscular Center

    Orange, California · Recruiting

  • The Regents of the University of California - San Diego

    San Diego, California · Recruiting

  • UCSF Movement Disorders Clinic

    San Francisco, California · Not yet recruiting

  • Children's Hospital Colorado - Center for Cancer and Blood Disorders (CCBD) - Anschutz Medical Campus Location

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Not yet recruiting

  • Novel Clinical Research Center, LLC

    Miami, Florida · Recruiting

  • Rare Disease Research, LLC

    Atlanta, Georgia · Recruiting

  • IU Health University Hospital

    Indianapolis, Indiana · Not yet recruiting

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland · Not yet recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine - Center for Advanced Medicine (CAM) - Neuroscience Center

    St Louis, Missouri · Not yet recruiting

  • Tekton Marlboro Neurology

    Marlboro, New Jersey · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Not yet recruiting

  • Akron Children's Hospital

    Akron, Ohio · Recruiting

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Neurology and Neuromuscular Care Center-Neurology Rare Disease Center

    Flower Mound, Texas · Not yet recruiting

  • Baylor College of Medicine (BCM)

    Houston, Texas · Recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia · Not yet recruiting

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia · Not yet recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Not yet recruiting

  • Perron Institute

    Nedlands, Western Australia, Australia · Not yet recruiting

  • Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven Gasthuisberg Campus

    Leuven, Belgium · Recruiting

  • Charles University and General University Hospital

    Prague, Czechia · Not yet recruiting

  • Copenhagen Neuromuscular Center, Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre Hospitalier Universitaire d'Angers

    Angers, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, France · Recruiting

  • Hopital Roger Salengro, CHRU de Lille

    Lille, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2

    Nice, France · Recruiting

  • CHU de NICE - Hôpital Archet 2

    Nice, France · Recruiting

  • Hopital Universitaire Necker Enfants Malades

    Paris, France · Not yet recruiting

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France · Recruiting

  • Hopitaux Universitaires de Strasbourg

    Strasbourg, France · Recruiting

  • Charite - Universitaetsmedizin Berlin

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Halle

    Halle, Germany · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.